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ABSTRACT

A NOVEL KUNITZ-TYPE SERINE PROTEASE INHIBITOR FROM THE HOOKWORM,
ANCYLOSTOMA CEYLANICUM. Aaron M. Milstone, Lisa M. Harrison, and Michael Cappello.
Section of Infectious Diseases, Departments of Pediatrics and Epidemiology & Public Health, Yale
University, School of Medicine, New Haven, CT.
Hookworms, blood feeding intestinal nematodes, infect more than one billion people in the
developing world. Because little is known about the role of protease inhibitors in the pathogenesis of
human hookworm disease, we have recently devised a molecular strategy aimed at isolating cDNAs that
encode related serine protease inhibitors from adult Ancylostoma ceylanicum, a human hookworm
parasite. Using a combination of RT-PCR and 3' RACE, we have recently cloned the first Kunitz-type
serine protease inhibitor from A. ceylanicum. The tr anslated sequence of the cDNA encoding the mature
Ancylostoma ceylanicum Kunitz-type Inhibitor 1 (AceKI-1) predicts a 68 amino acid protein with a MW
of 7889 Da and a presumed methionine residue at its putative P1 inhibitory reactive site. The AceKI-1
cDNA was cloned into the pET28a expression vector, and recombinant protein (rAceKI-1) was purified
from induced lysates of E. Coli transformed with the rAceKI-1/pET 28a plasmid. Using single stage
chromogenic assays, we have determined that rAceKI-1 is a potent inhibitor of the serine proteases
chymotrypsin (K* = 485 pM), porcine pancreatic elastase (K, = 277 pM), and human neutrophil elastase
(K* = 1.06 nM). The inhibitor shows weaker inhibitory activity against trypsin (K, = 21 nM) and no
activity against coagulation proteases factor Xa and thrombin. Additional studies have revealed that
soluble protein extracts from the hookworms A. ceylanicum, A. caninum and Necator americanus contain
identical inhibitory activities, suggesting that chymotrypsin/elastase/trypsin inhibition is a broadly
conserved evolutionary strategy of adult hookworms. To confirm this biological activity in vivo, we have
purified the native inhibitor from soluble extracts of A. ceylanicum, using size exclusion and rpHPLC
chromatographies. Work is currently underway to further characterize the unique mechanism of protease
inhibition by AceKI-1, as well as to determine its biologic role in parasite survival and the pathogenesis
of hookworm anemia.
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Introduction:
Hookworm infection affects up to one billion people in the developing world and
is a major cause of gastrointestinal blood loss and iron deficiency anemia. Hookworm
disease has plagued mankind for thousands of years. Physicians in ancient China were
quoted as describing those with “able to eat but too lazy to work yellow disease” (1). In
1880, an epidemic struck Italian laborers building a railway tunnel in the Swiss Alps,
afflicting them with what was tenned miner’s anemia. In an attempt to rid the
Southeastern United States of rampant infection, the Rockefeller Sanitary Commission
for the Eradication of Hookworm Disease was launched in 1909. Hookworms quickly
gained respect not just as the “germ of laziness”, but also as a major cause of clinical
disease. John D. Rockefeller hoped his Commission could help “relieve human
suffering”(2). Through increased public health awareness, the Commission spawned
research to study hookworm biology and the pathogenesis of hookworm disease (3).
Almost a century later, hookworm infection continues to plague approximately one fifth
of the world’s population. We now know, however, that the presence of hookworm in
their human host is not the problem; it is disease these hookworms cause that we hope to
eliminate.
In human populations the prevalence of hookworm infection depends upon the
presence of an environment that is suitable for development and survival of hookworm
eggs and larvae, an environment where soil is contaminated with feces, and where
humans are in contact with the contaminated soil (4). Consistently, hookworm infection
is predominant in parts of the rural tropics where poor sanitary conditions and the use of
human feces as fertilizer provide a favorable climate for parasite transmission.

?

Hookworms infect people of all ages with peak prevalence in late adolescence. An
increased rate of infection in older children and adults may result from a greater
likelihood of this group contacting contaminated soil. Prevalence of hookworm has been
reported as high as 87% in some areas of Kenya (5), but commonly 30% of people in a
population will have intense infections, harboring 70% of the total worm burden (6).
Ancylostoma duodenale is the most prevalent human hookworm pathogen and is

predominantly found in India, China, and Mediterranean areas of Africa and Europe, and
has been described in Latin America as well (7). A. ceylanicum is an infrequent parasite
of humans in India and Southeast Asia (8,9), but its ability to also affect other animals
including dogs, cats, and hamsters makes it one of the easier species to study using
animal models (10). Necator americanus, the New World hookworm, named because of
its widespread distribution in the Caribbean and the Americas, is also found in the Pacific
Islands, Sub-Saharan Africa, and Southeast Asia.

Figure 1: Necator americanus (left) and Ancylostoma duodenale (right)

Hookworms are nematodes of the family Ancylostomidae and are differentiated
by their buccal teeth or cutting plates (see figure 1). Two important genera of
hookworms, Ancylostoma and Necator, are responsible for most clinical disease in
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humans. Species of Ancylostoma, including A. braziliense (cat hookworm) and A.
caninum (dog hookworm) generally invade the human host percutaneously and cause

cutaneous larva migrans. Ancylostoma duodenale, A. ceylanicum, and Necator
americanus invade percutaneously, but they complete their lifecycle in the host,

becoming adult blood feeding worms.

Additionally, Ancylostoma can be transmitted by

oral ingestion of contaminated food or soil (11). Vertical transmission of A. caninum has
been demonstrated in the colostrum and milk of dogs, and although A. duodenale has not
been isolated human milk, a high prevalence of infection in infants and young children
has led to suggestions that it, too, can be transmitted vertically (12).
Hookworms infect humans by a rather indirect route (see figure 2). Adult female
worms in the host intestine produce thousands of eggs that are expelled in the host’s
feces. These eggs are best suited for damp, sandy, and friable soil in a warm and shady
climate, where they will hatch into microscopic larvae, feed on bacteria and organic
debris, and undergo two developmental molts (13). Larvae can live for up to a month in
the soil before entering a host to continue development. Third stage infective larvae will
migrate up in the soil and can exhibit “questing behavior” as they climb up a blade a
grass, stand upright, and sway, awaiting contact with a host.
Hookworms contact human skin typically on the feet and legs, where they enter
percutaneously by burrowing into the skin (14). In previously exposed individuals, an
inflammatory response leads to the accumulation of white blood cells and an often
intense itch.

The hookworm larva penetrates the epidennis, the basement membrane, the

lymphatics and venules in the skin, and is then carried in the circulation to the right side
of the heart. After reaching the pulmonary capillaries, the larva penetrates the lung
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parenchyma and ascends to the trachea before being coughed up and swallowed by the
host. In the small intestine the third stage infective larva undergoes two additional molts
sexually differentiates into a blood feeding adult, and attaches to the intestinal mucosa.

A. DUODENALE LARVA
MIGHT LIE DORMANT
IN TISSUE FOR A TIME
BEFORE CONTINUING
DEVELOPMENT

MLARVA
W
ENTERS
f AIRWAYS AND
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UP INTO MOUTH
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Figure 2: The lifecycle of A. duodenale. (13)
The lifecycle begins with development of the egg in the soil (1 -4). Infective larvae (L3) usually
penetrate the skin and follow the venous circulation to the lungs, eventually making their way to
the intestine (5-9). Mature adults copulate and eggs are excreted in feces to renew the lifecycle in
the soil (10,11). A. duodenale has been shown to establish infection following oral ingestion (5a).
L3 can migrate to tissues and remain dormant and other studies suggest the potential for breast
milk transmission.
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Within two months of arriving in the host as larvae, adult female worms lay eggs which
are passed with feces into the soil to continue the transmission cycle.
Dr. Gerhard Schad identified a divergence from this cycle when he demonstrated
A. cluodenale larvae’s ability for arrested development in their host (15). The infective

larvae can remain dormant for months in the host, often in skeletal muscle, before
maturing to a patent adult. Dormancy may have a selective advantage for hookworms. If
eggs are laid into soil that is dry and hot, then they will not survive. Arrested larvae have
been shown to resume development with seasonal periodicity, which leads to speculation
that larvae develop to peak ova-producing adults by onset of monsoon season,
presumably to ensure for egg deposition into moist soil (16).
The presence of a few hookworms in the human intestine is clinically benign, but
in cases of heavy worm burden, the resulting hookworm disease, namely iron deficiency
anemia, can be lethal (17). While in the small
intestine, most often the jejunum (18), the
hookworm attaches to the intestinal mucosa by
its specialized teeth (A. duodenale) or cutting
plates (N. americanus). The parasite’s muscular
pharynx creates negative pressure sucking in a
plug of mucosal membrane and underlying
tissue (see photo to right). Lysis of mucosal
cells and localized tissue damage leads to
rupture of capillaries in the lamina propria and
hemorrhage (19). Primary blood loss occurs as

blood passes through the intestine of the worm, and secondarily from leakage around the
worm’s attachment site (20). Bleeding also occurs at previous attachment locations as
worms move to new sites and from occasional extensive intestinal hemorrhage (21). It
has been estimated that each adult A. duodenale can cause 0.2 - 0.4 cc of blood loss per
day (22) while N. americanus are less aggressive feeders and result in only ten percent of
the blood loss of A. duodenale. As mentioned earlier, many infected people harbor few
worms, but those with high intensity infection are at risk for clinically significant blood
loss. In such cases, studies with A. duodenale and N. americanus infection have shown
daily losses of 4.8 mg iron (23) and 2 mg iron (24), respectively, up to five times the
daily median requirement of iron for a healthy school-age child. Plasma protein is also
lost in the blood and hypoproteinemia can be seen in heavily infected individuals.
Many studies have tried to correlate intestinal worm load, estimated by fecal egg
count, and the resulting anemia, measured by hemoglobin concentration (25). The
hemoglobin level, however, only declines when total body iron stores have been
depleted. The development of iron deficiency anemia, therefore, is dependent not only
upon the intensity and chronicity of infection, but also upon the host’s total body stores
and dietary iron intake. Children and women usually have the lowest iron stores and are
therefore most susceptible to developing iron deficiency anemia, especially in the context
of insufficient iron intake and malnutrition. Some studies have estimated that 20-80% of
iron and other blood constituents can be reabsorbed further along in the intestine;
however, common co-infections with Ascaris lumbricoides and Trichuris trichiura can
impair the absorptive surface of the gut (26). Ultimately, though, if the infection is
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treated and there is sufficient iron intake, then the hemoglobin levels will rise and the
anemia will resolve (27).
The most significant clinical complication from hookworm infection is the iron
deficiency anemia that results from chronic gastrointestinal blood loss. Growth
retardation is a sequela of iron deficiency that can be reversed by iron supplementation
(28). The effects of iron deficiency on mental performance, however, have been long
debated. Observations in the Southeastern United States that had termed hookworms the
“germ of laziness” also noted improvements in mental alertness that occurred following
treatment of heavily infected children (2). Studies have correlated iron deficiency anemia
in children with lower test scores on intelligence tests and decreased scholastic
performance. Although the mechanism for this is unknown, it has been shown that as
iron stores are depleted in the host, there is a decrease in iron containing enzymes such as
monoamine oxidase, an enzyme involved in the production of the neurotransmitters
serotonin, dopamine and norepinephrine (29).

Overall, Pollitf s in depth review of the

often contradictory literature concluded that hookworm infection can cause cognitive
impairment (5).
The ideal approach to prevention of hookworm infection relies on improvement in
the quality of life with better sanitation and water supplies as demonstrated in the
southeastern United States. Better sanitary systems, however, are not imminent in the
developing world. Popular literature has argued that wearing shoes would help reduce
transmission of hookworm, but arguments to the contrary point out the incidence of
reinfection from activated dormant larvae (11). Current strategies targeting hookworm
infection involve treatment with anthelmintic agents.

A single oral dose of albendazole

or mebendazole can remove adult hookworms from the small intestine. In endemic areas,
however, reinfection is common within 4-12 months of treatment. Additionally,
anthelminthics do not target dormant larvae, and in order to prevent anemia, multiple
courses of treatment are required (30). Although effective and inexpensive (by
developed nation standards), these drugs are contraindicated in patients with blood
dyscrasias, leukopenia, and liver disease, and concerns remain about embryo toxicity and
teratogenicity (7,24). Additionally, as has been seen with many classes of antibiotics, the
development of drug resistance is possible with continued widespread usage of
anthelminthics (31). The interventions present to target global hookworm disease, are
therefore either improbable or have potential risks.

Currently no human hookworm

vaccine exists mainly due to a lack of understanding of hookworm biology. Further
discovery of the requirements for parasite survival and the pathogenesis of hookworm
anemia will hopefully lead to the development of a novel treatment strategy to eliminate
hookworm disease.
Hookwonns secrete various molecules that potentially aid in parasite survival and
the pathogenesis of hookworm anemia. Targeting these virulence factors may serve as a
new approach to alleviating hookworm disease (32). As a result, killing the worm may
not be necessary to prevent disease; neutralizing the virulence factors that enable it to
blood feed and evade the host immune response may be sufficient. These substances
include anticoagulants, antiplatelet agents, protease inhibitors, proteases, hyaluronidases,
and anti-inflammatory agents. These molecules are presumed to enable hookwonns to
penetrate the skin, travel passively through the blood stream to lodge in the capillaries of
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the lungs, invade the intestinal mucosa, and cause sufficient blood loss to induce iron
deficiency anemia, all occurring in the absence of an effective host immune response.
Hookworms have evolved the ability to secrete molecules that facilitate tissue
invasion. The third stage (L3) infective larva of Ancylostoma caninum secretes a
hyaluronidase speculated to break the hyaluronan bridges connecting epidermal
keratmocytes and aid in percutaneous invasion (16). Secreted metalloproteases may also
play a role in breaking down connective tissue banners allowing the spread of other
secreted proteins (33). A proteolytic enzyme from adult A. caninum is produced
presumably for degrading and lysing the engulfed bolus of host intestinal mucosa (34).
Likewise, Necator americanus contains a variety of proteolytic activities in vitro, thought
to be responsible for digesting host tissues (35).
Hookwonns produce proteins, proteases, and protease inhibitors that may aid the
parasite in surviving the host environment and evading the immune response. A serine
protease inhibitor has been cloned from Ancylostoma caninum, named Catrin, with
specific inhibitory activity against trypsin (36). Inhibiting trypsin may enable the worm
to survive the hydrolytic environment of the gastrointestinal tract. A neutrophil
inhibitory factor (NIF) has been cloned from adult Ancylostoma caninum excretory and
secretory products (ES products), which binds to a GDI 1/CD18 receptor of neutrophils
and inhibits phagocytosis and the release of oxidants (37). A 42 kD protein, named
Ancylostoma Secreted Protein, has also been cloned from activated infective larval stage
Ancylostoma caninum ES products (38). This secreted protein has unknown function but

is similar in sequence to NIF. Proteases from A. caninum also demonstrate homology to
cysteine proteases from H. contortus that cleave immunoglobulins (39).

N. americanus
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secretes a superoxide dismutase and a glutathione-S-transferase, antioxidants that can
neutralize free radicals (40). All these substances are thought to help hookworms evade
destruction by interfering with the host environment and immune response.
Hookworms have also evolved the ability to enhance blood feeding by secreting
proteins and protease inhibitors that inhibit coagulation and platelet aggregation. This
phenomenon was described as early as 1910 by Loeb and Fleisher who described a
substance in hookworm homogenates that targeted and inactivated a host protein, thereby
inhibiting blood coagulation and facilitating blood loss (41). More recently, distinct
serine protease inhibitors from Ancylostoma caninum have been cloned and characterized
including AcAPc2, which has inhibitory activity against the complex of coagulation
factor Vila and tissue factor (42), and AcAP5, which has activity against coagulation
factor Xa (43, 44). A. caninum has also been shown to secrete a potent inhibitor of
platelet function which blocks platelet binding to immobilized fibrinogen and collagen by
the glycoproteins Ilb/IIIa and Ia/IIb (45). One can speculate that Ancylostoma has
evolved this complex strategy to block blood coagulation and platelet interaction to
facilitate and enhance blood feeding.
These hookworm proteins, proteases, and protease inhibitors are believed to be
essential components in the pathogenesis of human hookworm disease. Michael
Cappello’s laboratory is working to identify novel protease inhibitors from adult
hookworms, which ultimately may contribute to parasite survival within its mammalian
host. Some inhibitors may lead to increased blood loss and the development of anemia
and others may have different functions. More specifically. Dr. Cappello is targeting
serine protease inhibitors from Ancylostoma ceylanicum because this human parasite also

infects other animals including dogs, cats, and hamsters, and therefore can be studied as a
model for human disease (46).
As mentioned above, a number of serine protease inhibitors have been cloned
from adult hookworms. Both AcAP5 and AcAPc2 are members of the Ascaris family of
protease inhibitors, first identified in the non-blood feeding intestinal nematode Ascciris
suuni. Catrin, also cloned from A. caninum, is a trypsin inhibitor that belongs to the

Kunitz family. The serine protease inhibitors are divided into families based upon the
configuration of disulfide bridges and the sequential location of their reactive site (47)
(see discussion).

The pattern of intrachain disulfide bridges is conserved within families,

helping to categorize newly identified protease inhibitors. Some of the families include
the Kunitz (Bovine Pancreatic Trypsin Inhibitor) Family, the Kazal (Pancreatic Secretory
Trypsin Inhibitor) Family, the Bowman-Birk Inhibitor Family, the Serpins, and the
Ascaris Trypsin Inhibitor Family. It has been hypothesized that the AcAP inhibitors

facilitate hookworm blood feeding, while Catrin may protect the adult worm from
trypsin-mediated proteolysis within the mammalian intestine. Intuitively, one could
assume that these inhibitory activities represent a conserved evolutionary strategy for
survival in all species of hookworm. In such a case, these virulence factors would serve
as suitable targets for either drug or vaccine development. Therefore, Dr. Cappello
devised a molecular strategy to identify novel serine protease inhibitors from adult
Ancylostoma ceylanicum. More specifically, this project started with the goal of

identifying a factor Xa inhibitor from adult A. ceylanicum, similar to the Ascaris-type
inhibitor of coagulation factor Xa he had previously isolated from the dog hookworm
Ancylostoma caninum (42).
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Why are we interested in identifying and cloning novel protease inhibitors? We
hypothesize that these inhibitors serve as hookworm virulence factors and play a biologic
role in parasite survival and the pathogenesis of hookworm anemia. Because of their
likely role in parasite survival, interfering with protein virulence factors using
chemotherapeutics or immunotherapy can be a new therapeutic strategy at alleviating
hookworm disease .

STATEMENT OF PURPOSE:

Protease inhibitors have been identified in multiple species of hookworms. The purpose
of this research project was to identify novel serine protease inhibitors from Ancylostoma
ceylanicum that may act as virulence factors and play a biologic role in parasite survival

and the pathogenesis of hookworm anemia. We propose to use gene sequences from
previously identified protease inhibitors to facilitate our cloning efforts.
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Materials and Methods:

Hookworms: The life cycle of the hookworm Ancylostoma ceylanicum was maintained
in our laboratory by Dr. Richard Bungiro and Esfir Kruglov, using a previously described
hamster model (48). Infective third stage (L3) A. ceylanicum larvae were provided
initially by Drs. John Hawdon and Peter Hotez at Yale University School of Medicine.
Three week old Syrian hamsters (LVG strain) were infected orally by gavage with 100150 L3 per animal. Approximately 21 days post infection, the hamsters were euthanized
and the live adult hookworms harvested manually from the intestinal mucosa. Adult
Ancylostoma caninum were obtained from the intestines of laboratory infected dogs using

a similar protocol (49). Adult Necator americanus hookworms were harvested from
hamsters in the laboratory of Dr. David Pritchard of the Department of Life Sciences at
The University of Nottingham (Nottingham, England).
Hookworm Extracts and Excretory and Secretory Products : Extracts of adult
hookworms were prepared by manually homogenizing the adult worms in 50 mM TrisHC1 pH 7.5 using a glass homogenizer. Soluble protein extracts, which represented the
starting material for the purification and characterization of Ancylostoma ceylanicum
Kunitz-type Inhibitor-1 (AceKI-1), were obtained by centrifugation at 10,000 x g. Protein
concentrations of each lot of hookworm extracts were determined using the BCA reagent
from Pierce (Rockford, IL). Extracts of infective larval stage (L3) hookworms were
prepared similarly to the adult extracts.

Adult hookworm excretory and secretory

products (ES products) were prepared by incubating live, freshly harvested adult worms
in RPMI media with or without host serum (5%) overnight at 37° C in 5% C03. The
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worms were removed and the secretory products clarified by centrifugation at 10,000 x g
prior to use.
RNA Extraction: Fifty adult Ancylostoma ceylanicum were resuspended in 1.0 ml of
Trizol (Gibco/BRL; Gaithersberg, MD); total RNA isolation was carried out according to
the manufacturer’s protocol. In brief, 50 worms were homogenized in 1.0 ml Trizol and
incubated at 25°C for 10 min to allow for complete dissociation of nucleoprotein
complexes.

Following 5 min incubation with 200 pi of chloroform, the sample was

centrifuged and the aqueous phase removed. Total RNA was precipitated by incubating
the aqueous phase with 500 pi isopropyl alcohol at 25°C, followed by centrifugation.
The RNA pellet was washed with 75% and 100% ethanol, air dried for 10 min, and
resuspended in 40 pi diethyl pyrocarbonate (DEPC)-treated water.
Reverse transcription-polymerase chain reaction (RT-PCR) : RT-PCR of total adult
A. ceylanicum RNA was utilized to obtain the A. ceylanicum complementary DNA (50).

All primers were synthesized by the William Keck Foundation Biotechnology Resource
Laboratory at Yale University School of Medicine (see figure 3).
First strand cDNA was synthesized by incubating approximately 1 pg RNA, 10 mM
DTT and 100 ng 3’CKDGFYRD in Superscript 5X first strand reaction buffer (50 mM
Tris-HCl, 75 mM KC1, 3 mM MgCC, pH 8.3) (Gibco/BRL). The solution was heated for
90 sec at 90°C and cooled on ice.

Each of four deoxynucleotides (1 mM; dATP, dCTP,

dGTP,dTTP; New England Biolabs, Beverly, MA) was added along with 40 U RNasin
(Promega; Madison, WI) and 200 U reverse transcriptase enzyme (Superscript II; GibcoBRL). This mixture was incubated for 1 hr at 42°C and cooled on ice.
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1

3

5’
3’
2
(1)

5’SLXHO

5'GGAGAAGGACTCGAGGGTACTGCAGGGTTTAATTACCCA 3'
Xho\

(2) 3’ CKDGFYRD

5' GTCTCTGTAGAATCCGTCKTYGCA 3'

(3) 5’ KUNITZ1A
(4) 3’ TTTT

5'GGCGTTCTTCAAGAGGTACACCTAC 3 '

5’ ACEKIBAM

5'GGCCACGCGTCGACTACTTTTTTTTTTTTTTTT 3'
5'GGAGAAGTAGGATCCGCAGAGGAAGCAGGG 3'
BamH 1

3’ ACEKIXHO

5'GGATCTGGCTCGAGGCCTATTACTTTACACAAGTC 3'
Xho\

T7Promoter
M13Re verse

5'TAATACGACTCACTATAGGG 3'
5'CAGGAAACAGCTATGACC 3'

Figure 3 : Primers for cloning rAceKI-1
Initial cDNA sequence was obtained through RT-PCR using a sense strand PCR primer (1) which
corresponds to the nematode spliced leader sequence present in the 5’ region of many nematodes
mRNAs (51-53). A degenerate antisense strand primer (2) is homologous to a conserved region
(CKDGFYRD) observed near the carboxy-terminus of Ascctris-type inhibitors (42). To clone the
3’ end, RT-PCR with an antisense oligo (dT) primer (4) was used along with an internal primer
(3) designed from initial sequence.

The entire first strand cDNA mixture was combined with : PCR primers 5’SLXHO and
3’CKDGFYRD (100 ng each), PCR buffer (60 mM Tris-HCl, 15 mM NH4S04, 1.5 mM
MgCfi, pH 10.0), and 1 mM deoxynucleotides. The reaction mixture was brought to a 49
ml total volume with DEPC water. Amplitaq taq polymerase enzyme (5 U; Perkin-Elmer,
Foster City, CA) was then added and samples were placed in a thermal cycler (PCR
Sprint, Hybaid; Middlesex, UK) for 40 cycles (94°C for 15 sec denaturation, 55°C for 5
sec annealing, and 72°C for 30 sec extension). The PCR product reaction mixture was
subjected to 1% agarose gel electropheresis and visualized by ethidium bromide staining.
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3’ RACE (Rapid Amplification of cDNA Ends) : RT-PCR was performed, as above,
using 1 pg RNA and an antisense oligo (dT) primer, 3’ TTTT. The first strand cDNA
mixture was added to PCR reagents, including primers 3’ TTTT and 5’KUNITZ1A, an
internal primer designed to initial sequence obtained (see figure 3).

The mixture was

placed in the thermal cycler for 40 cycles, as above using same concentration reagents
and cycling conditions.
DNA Sequencing : The resulting PCR product was ligated into the pCR2.1 (Invitrogen;
Carlsbad, CA) TA cloning vector by incubating ~10 ng PCR product, 50 ng pCR 2.1
vector, T4 DNA ligase, and ligation buffer overnight at 14°C. One Shot E. coli INVaF’
(Invitrogen) were transformed with the ligation product as per manufacturer’s protocol.
In brief, after mixing the E. coli with 0.5 M B-mercaptoethanol, 10% of the ligation
product was added and incubated on ice for 30 min, followed by a 30 sec heat shock at
42°C and then 2 min on ice.

SOC medium was added to the transformed bacteria and

incubated for 1 hr at 37°C 250 RPM.

Samples were plated on LB agar plates with 30

pg/mL kanamycin (G1BCO/BRL) and grown overnight at 37°C. Colonies which grew on
the selective media were screened for the appropriate sized insert by direct colony PCR
using vector specific primers (T7 Promoter, M13 Reverse), and by restriction enzyme
digest (EcoRI; New England Biolabs) of isolated plasmid DNA. Miniprep plasmid DNA
(Spin Miniprep Kit, QIAGEN; Valencia, CA) from positive colonies was sent to the
William Keck Foundation Biotechnology Resource Laboratory at Yale University School
of Medicine for nucleotide sequencing.
Sequence Analysis : Sequences were analyzed for homology to other known sequences
using the BLAST algorithm through the National Center for Biotechnology Information
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(http://www.ncbi.nlm.nih.gov/BLAST/) (54).

The full length translated amino acid

sequence was analyzed using SignalP Program used for determination of the signal
sequence cleavage site (http://www.cbs.dtu.dk/services/SignalP/index.html) (55,56).
Expression of Recombinant AceKI-1 (rAceKI-1): In order to clone the entire AceKI-1
cDNA corresponding to the predicted mature protein into a prokaryotic expression
vector, RT-PCR was perfonned again, as above, using 3’ ACEKIXHO and 5’
ACEKIBAM primers.

The 5’ primer was designed based on the mature protein’s

predicted NPE-terminal amino acid residues. Purified rAceKl-1 cDNA (PCR Purification
Kit; QIAGEN, Valencia, CA) was digested with BamWX and Xho\ (New England
Biolabs) and directionally cloned into the pET28a expression plasmid vector (Novagen;
Madison, WI).

The pET28a plasmid encodes a polyhistidine fusion protein tag at the

amino terminus (AlaSerMetThrGlyGlyGlnGlnMetGlyArg) and a T7 Tag at the carboxy
end. The ligated pET28a plasmid containing the AceKI-1 cDNA was transformed into
ultracompetent E. coli strain BL21 (DE3) cells (Stratagene; La Jolla, CA) and samples
were plated on LB/kanamycin plates and grown overnight.

Colonies that grew on the

selective media were screened for the appropriate sized insert by direct colony PCR using
an AceKI-1 specific primer (3’ACEKIXHO) and a vector specific primer (T7 Promoter)
and by restriction enzyme digest {BamW 1 and Xliol) of plasmid DNA. Miniprep plasmid
DNA from AceKI-1 positive colonies was subsequently subcloned into E. coli strain
BL21 (pLysS) cells (Stratagene) for optimization of expression. Cells were plated on
LB/kanamycin plates and individual colonies screened by PCR for presence of AceKI-1
cDNA.

A colony of transformed BL21 (pLysS) E. coli with the rAceKI-1 :pET28a insert
was placed in a 50 mL culture of LB/kanamycin media and incubated at 37°C 250 RPM.
Log phase cultures (OD60o = 0.6 - 1.0) were induced by the addition of isopropyl-f3-Dthiogalactopyranoside (1PTG; Labscientific Inc., Livingston, NJ) at a 1 mM final
concentration and incubated for 3 hr with continuous shaking at 37°C.

One milliliter

aliquots were removed at 0, 1,2, and 3 hr post induction, centrifuged, and resuspended in
tricine SDS-PAGE sample buffer (4% SDS, 12% glycerol, 0.5 M Tris-HCl, pH 6.8,
0.01% Coomassie brilliant blue G) for SDS-PAGE and immunoblotting (see below).
SDS-PAGE and Immunoblotting : Aliquots from above protein expression culture were
incubated for 15 min 37°C in SDS-PAGE buffer. Approximately 10 pg of protein from
each time point was subjected to SDS-PAGE using a 13% polyacrylamide gel.

One

protein gel was stained with Coomassie stain (40% methanol, 10% acetic acid, and 0.1%
Coomassie Brilliant Blue R250 [BIORAD]) for one hour and then destained with a
solution of 30% methanol and 10% acetic acid for observation of increased protein
expression by induced bacteria. A second protein gel was used for Western blotting via
transfer to a 0.2 pm nitrocellulose membranes (BIO-RAD; Hercules, CA) by electro
blotting at 100V for 1 hr at 4°C. The membrane was incubated overnight at 4°C with
slow agitation in a 1:10,000 dilution of monoclonal HRP labeled antibody to the T7 tag,
5% milk, 0.05% Tween in PBS. After three washes in PBS 0.1% Tween, bands were
visualized using a chemiluminescent substrate (SuperSignal West Pico, Pierce; Rockford,
IL) and auto radiographic film (Kodak).
Recombinant AceKI-1 Protein Purification : A 2-liter culture of log-phase BL21
(pLysS) cells containing the pET28a:rAceKI-l plasmid was induced as above with 1 mM
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IPTG.

At 3 hr post-induction the cells were iced for 5 min, centrifuged at 4°C 5,000

RPM, and resuspended in 1/10 the original culture volume of binding buffer (5 mM
Imidazole, 500 mM NaCl, 20 mM Tris-HCl pH 7.9). The solution was sonicated using a
Branson 450 Sonifier (50% Duty cycle, output 2) and centrifuged at 13,000 RPM for 20
min at 4°C to separate soluble and insoluble fractions. The soluble supernatant from the
induced cell lysate was applied to a Hi-Trap (Amersham Pharmacia Biotech AB;
Uppsala, Sweden) 5 mL bed volume nickel resin affinity column charged with 50 mM
NESCE at 25°C and equilibrated with binding buffer. The column was washed with a 60
mM imidazole buffer and eluted with 1 M imidazole buffer (Novagen His-Bind Buffer
Kit).

Approximately 500 ng of partially purified protein and protein standards

(GIBCO/BRL) were analyzed by SDS/PAGE and Western blotting, as described above.
Following nickel resin affinity chromatography, the partially purified recombinant
protein was subjected to reverse-phase HPLC using a Cis column (Vydac; Hesperia, CA).
The bound protein was eluted with a linear gradient of 0-60% acetonitrile in 0.1% TFA.
Individual peaks of protein as detected by absorbance at 214 nm were collected and
assayed for serine protease inhibitory activity (as described below).
Recombinant

Protein

Analysis

:

An aliquot

from

rpHPLC

was

subjected

to

Electrospray Ionization Mass Spectrometry (ESMS) using a Micromass Q-Tof mass
spectrometer by the William Keck Foundation Biotechnology Resource Laboratory at
Yale School of Medicine. Electrospray ionization Mass Spectrometry (ESMS) is used to
determine the molecular mass and purity of low molar amounts of proteins and peptides
(57).

20

An

aliquot

from

rpHPLC

was

sent

to

the

William

Keck

Foundation

Biotechnology Resource Laboratory for amino acid analysis. A Beckman Analyzer was
used to determine the molar concentration of the purified inhibitor.

This molar

concentration was used to characterize rAceKI-l’s inhibitory kinetics, see below (58).
Assays of Protease Inhibition : Single stage chromogenic kinetic assays were used to
characterize the inhibitory activity of r-AceKI-1 against six serine proteases (59).
rAceKI-1 was preincubated with each of the enzymes listed below for 15 min at 25°C
followed by addition of the appropriate chromogenic substrate. In a total volume of 200
pi in individual wells of a 96-well microtiter plate, the concentration (expressed as final
concentrations) of enzyme/substrate were as follows: porcine pancreatic elastase (1.5 nM;
Sigma Aldrich, St. Louis, MO)/ Suc-Ala-Ala-Pro-Ala-pNA (250 pM; Bachem, Torrence,
CA); human neutrophil elastase (7.5 nM; Calbiochem, La Jolla, CA)/ Elastase Substrate 1
(250 pM; Calbiochem); bovine pancrease a-chymotrypsin (3 nM; Sigma)/ Suc-Ala-AlaPro-Phe-pNA (200 pM, Bachem); bovine pancrease trypsin (4 nM; Sigma)/ S2302 (250
pM; DiaPharma, West Chester, OH); factor Xa (1.0 nM, Sigma)/ S2765 (250 pM;
DiaPharma); a-thrombin (0.5 nM; Sigma)/ S2238 (250 pM; DiaPharma).

The kinetic

rate of substrate hydrolysis (mOD/min) at 405 nM was measured over 5 min using a
kinetic microplate reader (MRX HD; Dynex Laboratories, Chantilly, VA). Results were
expressed as percent inhibition of rAceKI-1 activity using the following formula: percent
inhibition = 1 - inhibited rate/uninhibited rate x 100.
By

using the

single-stage chromogenic
•

assay described

•••••

above,

we

then

He

established the apparent equilibrium dissociation inhibitory constant, K, (60,61), for
purified rAceKI-1 against pancreatic elastase, human neutrophil elastase, chymotrypsin.

and trypsin. In each microtiter well, varying rAceKI-1 concentrations were incubated for
15 min with a fixed enzyme concentration, as above. Substrate was then added at a final
concentration of five times the Kin and the initial rate (mOD/min) of substrate hydrolysis
over 5 min was measured at 405 nm. This assay was repeated using increasing amounts
of inhibitor and the ratio of inhibited velocity (V() to uninhibited velocity (V0) was
plotted against the corresponding rAceKI-1 concentration.

All experiments were

performed in triplicate, and these kinetic data were fit to the Morrison equation for the
■
•••
•
^
analysis of tight binding protease inhibitors to derive the K, for rAceKI-1 (62,63).
Purification of native AceKI:

In collaboration with Dr. Richard Bungiro at Yale,

soluble extracts from 200 adult A. ceylanicum (see above preparation) were applied to a
300x7.5 mm size-exclusion chromatography column (Bio-Sil TSK-125; BIO-RAD,
Hercules, CA) that was equilibrated with 50 mM Tris-HCl, pH 7.5 and 0.2 M NaCl.
Individual fractions were tested for serine protease inhibitory activity, as described
above, and active fractions were pooled.

The molecular mass of the presumed native

AceKI was estimated by extrapolation from a standard curve (logmoiecuiar mass vs. retention
factor [Rf]) constructed from the elution profile of a mixture of protein standards (BIO¬
RAD) with known molecular masses.
Following size-exclusion chromatography, the pooled active fractions were
subjected to reverse-phase HPLC using a Cjg column (Vydac; Hesperia, CA).

The

bound protein was eluted with a linear gradient of 0-60% acetonitrile in 0.1% TFA.
Individual peaks of protein as detected by absorbance at 214 nm were collected and
reassayed for serine protease inhibitory activity.
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Native Protein Analysis : An aliquot of rpHPLC purified native AceKI-1 was subjected
to matrix-assisted laser desorption ionization mass spectroscopy (MALDI-MS) by the
William Keck Foundation Biotechnology Resource Laboratory at Yale School of
Medicine to determine molecular mass. MALDI-MS uses a research grade, VG TOFspec
SE instrument equipped with delayed extraction and a reflectron.

Masses can he

determined with an average mass accuracy of ±0.1% with external calibration (64).
To confirm that the purified native protein corresponded to rAceKI-1, a sample
was sent to the William Keck Foundation Biotechnology Resource Laboratory at Yale
School of Medicine for NFL-terminal amino acid sequencing.

The amino terminal

sequencing is earned out on an Applied Biosystems sequencer equipped with an on-line
HPLC system (58).
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Results:
Cloning of AceKI-1 cDNA Sequence : To obtain initial cDNA sequence of AceKI-1
Lisa Harrison used a sense strand PCR primer corresponding to the nematode spliced
leader (SL) sequence present in the 5’ region of many nematodes mRNAs (51-53) and a
degenerate antisense strand primer homologous to a conserved region (CKDGFYRD)
located near the carboxy-terminus of Ascaris-type inhibitors (42). Using these primers, a
cDNA fragment of approximately 250 bp was amplified from total adult Ancylostoma
ceylanicum RNA.

Translated amino acid sequence of the initial AceKI-1 cDNA

demonstrated homology to members of the Kunitz family of serine protease inhibitors
(see

discussion),

including

tissue

factor

pathway

inhibitor

and

the

silkworm

chymotrypsin inhibitor (see Figure 5).
The partial cDNA contained the spliced leader and the 5’ ATG initiation codon,
but not the 3’ poly(A) tail. I began my project by isolating the 3’ end of AceKI-1 from
adult A. ceylanicum using RT-PCR and a 3' RACE technique with a newly designed
internal primer and an oligo (dT) primer.

This yielded an approximately 300 bp

fragment. Three separate 3’ end clones were sequenced and contained identical
overlapping sequence with the initial cDNA. The full length AceKI-1 cDNA contains an
open reading frame of 252 nucleotides (see figure 4). The translated AceKI-1 amino acid
sequence was analyzed using the SignalP Program, a signal peptide prediction program.
The SignalP Program strongly predicted a 16 amino acid signal sequence with the
cleavage site of the translated protein to be located between residues 16 and 17 (C-A) of
the full-length clone.
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-30

21
71
121
171
221
271
321
371

TTACCCAAGTTTGAGAAGTCGTCGCCGTAAATGAAGGGTCTTCTGGTGGT
GCTGCTTTGTGTTGCGATCGCCTATTGCGCAGAGGAAGCAGGGAAGAAGC
T GAC AGAC GAGGAGAGAT GT AAT GC T C C GAC T C AC C T AGAT GGAC C AC AA
T GC AT GGCGTTCTT C AAGAGGT AC AC C T AC AAC AAGGAAAAGAAGC AAT G
CGAAGAATTCGTTTATGGAGGATGCCGCCCATCTCCAAACAACTTTGAGA
CGATGGAGGAGTGCAAGAAGACTTGTGTAAAGTAATAGGCAACGGCTCTG
GTAGAACGCAGTACAAGAAGAGGTCTTCGACTGCTTGAAAAACTATTATT
CCTTCTCAACATTATGCTGTAAGCTCTTCATTGTTTGCTCGTGAGATACC
ATTGCGTATAAATGGCAGAGTAGTGCAAAAAAAAAAAAAAAAAAA
Putative
Signal

sequence

LPKFEKSSP* MKGLLWLLCVAIAYCAEEAGKKLTDEERCNAPTHLDGPQ

cmaffkrytynkekkq£eefvyg3crpspnnfetmeeckktcvkadnnft
QETAMTMITPSLVPSSDPLVTAASVLEFGLAFFKRYTYNKEKKQCEEFVY
GGCRPSPNNFETMEECKKTCVK* *ATALVERSTRRGLRLLEKLLFLLNIM
L*ALHCLLVRYHCV*MAE*CKKKKKKSSRRVAKPNSADIHHTGGRSSMHL
EG

Figure 4 : AceKI-1 nucleotide sequence and deduced amino acid sequence.
AceKI-1 (in bold) consists of 252 base pairs with a deduced protein sequence of 82 amino acids.
Initiation of translation was based on the first ATG downstream of the nematode SL sequence.
The protein has a 16 amino acid signal sequence (lightly shaded) whose cleavage site was
predicted between residues 16 (C) and 17 (A)(underlined). The mature protein is 68 amino acids
followed by a TAA stop codon (darkly shaded). Interestingly, the AceKI-1 nucleotide sequence
corresponding to the initial 3’ primer (CKDGFYRD)(circled) has only 14 of 22 matching
nucleotides. The complete cDNA was submitted to GenBankIM with accession number
AF172651.
The translated sequence of the AceKI-1 cDNA predicts a mature protein of 68 amino
acids with a MW of 7889 Da and a pi of 6.79.
Homology of AceKI-1:

Analysis of the translated amino acid sequence using the

BLAST algorithm revealed AceKI-l’s homology to other Kunitz-type inhibitors,
including the chymotrypsin inhibitor from the silkworm Bombyx mori (65), a trypsin
inhibitor from Ancylostoma caninum (36), and multiple domains of human and rat tissue
factor pathway inhibitor (36,66).

The location of cysteine residues in AceKI-1 (see

figure 5) suggest that this is the first Kunitz-type serine protease inhibitor identified from
this species of human hookworm (see discussion).
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Figure 5 : AceKI-1 amino acid sequence homology.
Initial BLAST results revealed AceKI-l’s homology to Kunitz-type inhibitors including a
chymotrypsm inhibitor from the silkworm Bombyx mori, Catrin, two domains of human Tissue
Factor Pathway Inhibitor, and all three domains of 7?. rattus Tissue Factor Pathway Inhibitor.
Catrin, a trypsin inhibitor previously cloned from A. caninum, is the only other Kunitz-type
protease inhibitor reported to date from adult hookworms. The cysteine residues involved in
disulfide bridges are shaded in light gray. The P| reactive site residues are bold faced and
underlined, along with the postulated P| methionine of AceKI-1 (see discussion).
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Expression and Purification of Recombinant AceKI-1

: The cDNA

fragment

corresponding to the mature 68 amino acid AceKI-1 was cloned in-frame into the
pET28a prokaryotic expression vector.

Lysates of induced cells were separated using

SDS-PAGE under non-reducing conditions.

After Coomassie staining, no bands were

visualized that would suggest an obvious increase in protein expression following
induction. Western blots, however, using a monoclonal antibody against the pET28a
fusion protein T7 Tag confirmed the presence of the rAceKI-1 fusion protein in the
soluble fraction.
Having established that AceKI-1 was capable of being expressed in E. coli, the
pET28a-rAceKI-l fusion protein was induced in large-scale culture at an estimated
concentration of 0.5 mg/L.

Induced cell lysates were applied to a nickel resin affinity

column. The partially purified recombinant protein was subjected to reverse-phase High
Pressure Liquid Chromatography using a Cis column. The bound protein was eluted with
a linear gradient of 0-60% acetonitrile in 0.1% TFA.

Individual peaks were tested for

serine protease inhibition. Recombinant AceKI-1 eluted at an acetonitrile concentration
of approximately 26% (see figure 6).
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Figure 6 : Purification of recombinant AceKI-1 by reversed phase HPLC
Following nickel resin chromatography, the partially purified recombinant protein was subjected
to reversed-phase HPLC using a C]8 column. The bound protein was eluted with a linear gradient
of 0-60% acetonitrile in 0.1% TFA. Individual peaks were tested for inhibition of chymotrypsin
and elastase. rAceKl-1 eluted at approximately 26%.
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The purified recombinant protein was further characterized by ESMS (see Figure 7), and
results show a predominant peak with molecular mass of 11,293 Daltons, compared to a
predicted molecular mass of 11,451 Daltons [mature protein (7889 Da) + fusion tag
(3562 Da)], a 1.4% difference. Quantitative amino acid analysis was performed on the
rpHPLC purified protein in order to determine the molar concentration of the protein
sample.

ACEKI1
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Figure 7 : Electrospray Ionization Mass Spectrometry (ESMS) of recombinant AceKI-1.
The William Keck Foundation Biotechnology Resource Laboratory at Yale School of Medicine
subjected an aliquot from rpHPLC representing purified rAeeKI-1 to ESMS. Results show a
predominant peak with molecular mass of 11,293 Da., compared to a predicted molecular mass of
of 11.451 Da.
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Serine Protease Specificity : The selectivity of rAceKI-1 was examined against 6 serine
proteases, and inhibitory activity was demonstrated against chymotrypsin, pancreatic
elastase, human neutrophil elastase, and trypsin. At a molar ratio of 2:1, rAceKI-1
:enzyme, there was no detectable inhibition of factor Xa or thrombin.

We then used

single stage chromogenic assays to measure the rate of enzyme hydrolysis of
chromogenic substrate in the presence of increasing concentrations of rAceKI-1. These
kinetic data were fit to the Morrison equation developed for the analysis of tight binding
inhibitors, generating an apparent equilibrium dissociation inhibitory constant (AT, ) for
porcine pancreatic elastase chymotrypsin, human neutrophil elastase, and trypsin (see
Table 1 and Figures 8).

Table 1
Enzyme

-kT-

Porcine pancreatic elastase

277 pM +/- 71 pM

Chymotrypsin

485 pM +/- 102 pM

Human neutrophil elastase

1.06 nM+/- 427 pM

Trypsin

21 nM +/- 3.8 nM

A Equilibrium Dissociation Inhibitory Constant

1.0

0.8

0.6

A/ A
0.4

0.2

0.0

4

6

8

10

rAceKI-1 (nM)
Figure 8 : Inhibitory Kinetics of recombinant AceKI-1.
rAceKI-1 in increasing concentrations was incubated with trypsin, chymotrypsin, pancreatic
elastase, and neutrophil elastase followed by addition of chromogenic substrate. The velocity of
substrate hydrolysis in the presence of rAceKI-1 (V,) and the absence of rAceKI-1 (V0) was then
measured as described in the Materials and Methods. The observed velocity data (solid lines)
was tit to the Morrison equation for the evaluation of tight binding inhibitors. V,/V0 = [E - I
A/*] + [(I + Ki* - E)2 + 4A,*E]i/2/2E where E and 1 are the total amount of enzyme and inhibitor,
respectively, and K, is the apparent equilibrium dissociation inhibitory constant for purified
rAceKI-1 against pancreatic elastase, chymotrypsin, human neutrophil elastase and trypsin
(60,61).
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Life cycle Stage Specificity: Having characterized rAceKI-l’s inhibitory activity, I
wanted to determine whether a similar native activity was present in different
developmental stages of A. ceylcinicum. Soluble protein extracts from both infective third
stage (L3) Ancylostoma ceylcinicum larvae and adult A. ceylcinicum were therefore tested
for inhibitory activity against pancreatic elastase, human neutrophil elastase, trypsin, and
chymotrypsin. While adult extracts inhibited all four enzymes, L3 extracts only inhibited
human neutrophil elastase (see figure 9).

These data suggest that AceKI-1 is not

produced in significant amounts by the L3 stage ofhookwonns (see discussion).

A. ceylcinicum Adult

A. ceylcinicum Infective

Extracts (2 pg)

Larval Stage Extracts (2 jug)

Chymotrypsin (3 11M)

87%a

4%

Trypsin (4 nM)

80%

14%

Pancreatic Elastase

77%

16%

79%

59%

(1.5 nM)
Human Neutrophil
Elastase (7.5 nM)
A Percent inhibition of each enzyme by stage specific soluble protein extracts
Figure 9 : Lifecycle stage specificity of AceKI-1 activity.
Soluble protein extracts from both adult and L3 A. ceylcinicum demonstrate inhibitory activity
against human neutrophil elastase, but L3 extracts have virtually no significant inhibit activity
against chymotrypsin, trypsin and pancreatic elastase. This suggests that AceKI-1 is expressed
only during specific stages in the hookworm lifecycle (see discussion).
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Excretory and Secretory (ES) Products:

After demonstrating a similar inhibitory

activity to AceKl-1 in adult Ancylostoma ceylanicum extracts, 1 wanted to determine if a
similar activity was present in ES products. Adult A. ceylanicum ES products (as
described in Methods) were therefore tested for inhibitory activity against pancreatic
elastase, trypsin, and chymotrypsin.

The results demonstrate that adult ES products

effectively inhibited pancreatic elastase (79%), chymotrypsin (66%), and trypsin (56%)
compared to RPMI media/hamster sera alone (see Figure 10)

Figure 10 : Inhibitory activity of native AceKI-1.
ES products from adult A. ceylanicum are compared to soluble protein extracts of adult A.
ceylanicum for their respective inhibition of pancreatic elastase (1.5nM), trypsin (4nM), and
chymotrypsin (3nM). Both adult A. ceylanicum extracts and E/S products inhibit pancreatic
elastase, chymotrypsin and trypsin. The inhibitory profile of native AceKI-l is therefore similar
to that of recombinant AceKI-1. Data illustrated as percent activity (1- percent inhibition)
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Species Specificity:

Equal amounts of soluble protein extracts from adult hookworms

Ancylostoma ceylanicum, Ancylostoma caninum, and Necator americanus were screened
for inhibitory activity against pancreatic elastase, trypsin, and chymotrypsin.

All these

hookworm species contained comparable inhibitory activity against these three enzymes
(see figure 1 1). Chymotrypsin was inhibited by A. ceylanicum (92%), A. caninum (91%),
and N. americanus (94%); trypsin was inhibited by A. ceylanicum (75%), A. caninum
(88%), and N. americanus (90%); pancreatic elastase was inhibited by A. ceylanicum
(95%), A. caninum (93%), and N. americanus (89%).

Assuming that this inhibitory

activity is due to AceKI-1, these data suggest that AceKI-1 is broadly conserved across
evolutionary distinct hookworm species.

Chymotrypsin

Pancreatic
Elastase

Trypsin
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Figure 11 : Conservation of AceKI-1 inhibitory activity across hookworm species.
5 pg of soluble protein extracts from A. ceylanicum, A. caninum, and N. americanus were
screened for activity against pancreatic elastase (1.5nM), trypsin (4nM), and chymotrypsin
(3nM). Chymotrypsin, trypsin and pancreatic elastase inhibitory activity is present in all
three species, suggesting that inhibition of these three serine proteases is broadly conserved.

Purification of native AceKI: In order to prove that the activity in soluble protein
extracts corresponds to the AceKI-1 cDNA gene product, with the help of Dr. Richard
Bungiro, I purified the native inhibitor from adult A. ceylanicum.

Fractions from size

exclusion chromatography of soluble adult hookworm extracts were measured for
inhibitory activity against chymotrypsin and elastase. The activity eluted at an estimated
weight of approximately 9 kDa, based on extrapolation from a standard curve constructed
with proteins of known molecular mass.

The pooled samples of chymotrypsin and

elastase inhibitory activity were then subjected to lpHPLC on a Cig column.

All of the

anti-chymotrypsin and anti-elastase activity eluted in a single protein peak at an
acetonitrile concentration of approximately 26% (see figure 12). Likewise, the rAceKI-1
fusion protein eluted from the same Cis column at a concentration of acetonitrile of
approximately 26%.
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Figure 12 : Purification of native AceKI-1 by reversed phase HPLC
Following size exclusion chromatography, the partially purified protein was subjected to
reversed-phase HPLC using a C18 column. The bound protein was eluted with a gradient of 060% acetonitrile in 0.1% TFA. Individual peaks were tested for inhibition of chymotrypsin and
elastase. Native AceKI-1 eluted at approximately 26% (black arrow)
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The native protein was further characterized by MALDI-MS (see figure 13), which
revealed a single major peak with a molecular weight of 7882 Daltons, compared to the
predicted molecular weight of 7889 Da based on the translated sequenceof the AceKI-1
cDNA. This difference of 7 Da (0.08%) is within the range of error for the MALDI-MS
measurements of protein mass.
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Figure 13 : Matrix-Assisted Laser Desorption Ionization Mass Spectroscopy (MALDIMS) of native AceKI-1.
The William Keck Foundation Biotechnology Resource Laboratory at Yale School of Medicine
subjected an aliquot from rpHPLC representing purified native AceKI-1 to MALDI-MS. Results
show a predominant peak with molecular mass ot 7,882 Da., compared to a predicted moleculai
mass of 7889 Da.

37

In order to confirm that the native protein was, in fact, AceKI-1, the purified inhibitor
was submitted to the William Keck Foundation Biotechnology Resource Laboratory at
Yale School of Medicine for NFL-terminal sequence. The first eight NFL-terminal amino
acid residues from the purified protein were identical to the first eight amino acid of the
translated AceKI-1 cDNA, confirming identity of the native and recombinant proteins.
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Discussion:
Hookworms, blood feeding intestinal nematodes, infect more than one billion
people in the developing world. The most significant clinical complication from
hookworm infection is iron deficiency anemia, resulting from chronic gastrointestinal
blood loss. Women and children often have lower total body iron stores and are therefore
most susceptible to developing hookworm anemia. In children, heavy infection is
associated with lower scores on intelligence tests and decreased scholastic performance.
Current strategies targeting hookworm disease revolve around the use of anthelminthics.
With growing concern of drug resistance and drug toxicity, the search for alternative
control tactics continues. Dr. Cappello’s laboratory is working to identify novel protease
inhibitors from adult hookworms that aid in parasite survival and contribute to the
pathogenesis of hookworm anemia. Ultimately, interfering with these parasite virulence
factors may serve as a novel therapeutic strategy to alleviating hookworm disease.
I report here the first Kunitz-type serine protease inhibitor isolated from adult
Ancylostoma ceylanicum, a blood feeding hookworm. The translated sequence of the
Ancylostoma ceylanicum Kunitz-type Inhibitor 1 (AceKI-1) cDNA predicts a mature
protein of 68 amino acids with a MW of 7889 Da. The AceKI-1 cDNA was cloned into a
prokaryotic expression vector and recombinant AceKI-1 (rAceKI-1) was purified using
nickel resin affinity and rpHPLC chromatographies. The molecular weight of rACeKI-1
was confirmed by mass spectroscopy. Single stage chromogenic assays revealed that
rAceKI-1 is a potent inhibitor of the serine proteases chymotrypsin (K)* = 485 pM),
porcine pancreatic elastase (K,* = 277 pM), and human neutrophil elastase (K,* = 1.06
nM). The inhibitor demonstrates weaker inhibitory activity against trypsin (AT,* = 21nM)
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and no detectable activity against coagulation proteases factor Xa and thrombin. After
identifying this biological activity in vivo, we purified native AceKI-1 (nAceKI-1) from
soluble extracts of adult Ancylostoma ceylanicum using size exclusion and rpHPLC
chromatographies. Yale’s Keck Foundation Biotechnology Resource Laboratory verified
the native protein’s molecular weight using mass spectroscopy. NFL-terminal amino acid
sequencing of nAceKI-l’s first eight residues confirmed identity of the native and
recombinant proteins.
AceKI-1 is the first Kunitz-type protease inhibitor isolated from Ancylostoma
ceylanicum. As discussed earlier, serine protease inhibitors are divided into families
based upon the configuration of disulfide bridges and the sequential location of each
reactive site (47).

The pattern of intrachain disulfide bridges is conserved within

families, helping to categorize newly identified protease inhibitors. Some of the families
include the Kunitz (Bovine Pancreatic Trypsin Inhibitor) Family, the Kazal (Pancreatic
Secretory Trypsin Inhibitor) Family, the Bowman-Birk Inhibitor Family, the Serpins, and
the Ascaris Trypsin Inhibitor Family.
Protease inhibitors are ubiquitous in nature, generally functioning to prevent
undesired proteolysis. Most protease inhibitors target only proteases belonging to a
specific class. Their action relies on presenting an endogenous peptide bond, a reactive
site, as a substrate to the target enzyme and forming a classic lock and key interaction.
Protease inhibitors are divided into classes by the mechanistic action of their inhibition;
some inhibit carboxyl, metalo and sulfhydryl proteinases, and others inhibit serine
protease. Serine protease inhibitors are the best characterized and understood, and
although there are many heterogeneous subfamilies, they do have a similar mechanism of
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action. The reactive site of each inhibitor interacts with the respective active site of its
associated enzyme. A stable complex is formed and hydrolysis occurs very slowly as if
the coupling was being maintained at equilibrium.

Each reactive site residue, denoted as

Pi, generally designates the specificity of a given inhibitor for a particular protease (67).
In order to categorize and characterize a novel protease inhibitor we use BLAST
searches looking for amino acid sequence homology to previously described inhibitors.
All members of the Ascaris family, for example, share five intramolecular disulfide
bridges (68) and 30-40% amino acid sequence identity (69). Kunitz inhibitors are
approximately 60 amino acid residues in length, are generally tight binding inhibitors
(70), and their six cysteine residues fonn three disulfide bridges in the characteristic
pattern : 1-6, 2-4, 3-5 (71).

rAceKI-1 demonstrates strong homology to members of the

Kunitz family based on its spacing pattern of cysteine residues and postulated Pi reactive
site (see figure). By examining the amino acid sequence and comparing it to other
protease inhibitors, we can postulate its mechanism of inhibition of chymotrypsin,
pancreatic elastase, human neutrophil elastase, and trypsin.
In order to elucidate AceKI-l’s mechanism of inhibition, we will first look at the
reactive site amino acid residue and the structural interactions of other Kunitz inhibitors.
Bovine Pancreatic Trypsin Inhibitor (BPTI) was the first Kunitz inhibitor to be
characterized on a structural level and serves as a model for other Kunitz inhibitors.
Studies of the molecular structure of BPTI’s reactive site and side chain interactions have
helped to explain why amino acids in this region determine the specificity by which
Kunitz inhibitors bind proteases. The tertiary structure of BPTI suggests the reactive site
is an external loop held stable and rigid by interactions with its own core molecule and an
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additional minor loop (72). This external loop contains the reactive site, P| residue,
where primary interaction occurs with the cognate protease’s catalytic site, the Si
principal specificity cavity (73) (see figure 14). This inhibitor:protease complex is
stabilized by van der Waals interactions between the carbonyl carbon of the Pi residue
and the nucleophilic oxygen of the
catalytic protease side chain (74).
Water molecules fill the grooves as
permitted, strengthening the
interaction with hydrogen bonds. This
reactive site loop and active site cleft
form a tight interaction with little free
energy, thereby requiring a high

activation energy for hydrolysis and

Figure 14 : TFPI Domain 1 (76)

dissociation (75). The scissile bond of

This diagram, based on the secondary structure of
BPTI, illustrates the ammo acid sequence of TFPI
domain 1, which is homologous to AceKI-1. Three
cysteine-cysteine disulfide bonds between can be
seen as is the protease inhibitor’s external loop,
residues 30-50. At location 36 is the P| lysine. The
conserved GPC, P2 - P4, should be noted and will be
seen discussed below.

these tight binding inhibitors,
therefore, remains intact as it
undergoes slow hydrolysis (77). The

interaction between the Pi residue and the Si cleft is determined by the amino acids in the
area of the reactive site; specifically, the side chains of the Pi residue itself and those of
its surrounding amino acids, and their ability for polar interaction.
Based on the selective interactions of reactive site residues and their cognate
enzyme’s catalytic site, we expect proteases to bind preferentially to certain P, amino
acid residues. For example, chymotrypsin is selective for peptide bonds on the carboxyl
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side of large hydrophobic or aromatic residues. Chymotrypsin has a large SI cleft with a
neutral serine and can bond well with aromatic side chains of phenylalanine or a
hydrophobic methionine (73). In general, the following Pi residues commonly interact
with the respective proteases: tyrosine, phenylalanine, leucine, and methionine with
chymotrypsin; leucine and arginine with trypsin; leucine, methionine, and valine with
elastase (78). The nature of interaction between proteases and reactive sites will
determine the overall specificity; resultingly, strong inhibition of chymotrypsin and
elastase tends not to be seen concurrently with strong inhibition of trypsin. AceKI-1 ’s
interaction with chymotrypsin, however, is therefore consistent with its postulated PI
methionine (discussed below).
Understanding how reactive site residues and cognate enzymes interact illustrates
why the activity of Kunitz inhibitors depends upon the properties of their Pi amino acid
residues. BPTI, for example, a strong inhibitor of trypsin, has a Pi lysine that weakly
interacts with chymotrypsin. Carboxamidomethylation and reduction of the primary
disulfide bond eliminates the chymotrypsin activity while retaining the trypsin activity,
presumably by altering bonding interaction between the catalytic sites (79,80).
Chymotrypsin inhibitors have been identified from cobra venom of Naja naja naja, the
silkworm Bonibvx mori, and venom of Vipera ammodytes and their Pi residues are
phenylalanine, phenylalanine, and leucine, respectively (81). A Kunitz-type trypsin
inhibitor from Fasciola hepatica was identified with Pi leucine (82). Leucine is not
characteristically complexed with trypsin, which might explain why this inhibitor has a
high dissociation constant and is not tight binding.
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Comparing protease inhibitor homologues from humans and pigs demonstrates
the role that the reactive site amino acid residue plays in determining the specificity of
interaction between inhibitors and cognate enzymes. Human Inter-a-Trypsin Inhibitor
(HITI) is a well-characterized bidomain Kunitz-type inhibitor of trypsin found in many
species of mammals. HITI’s C-terminal domain, which inhibits trypsin strongly and
chymotrypsin weakly, has arginine at its Pi residue (83). The N-terminal domain has a Pi
methionine, weakly inhibits polymorphonuclear (PMN) granulocyte elastase, and has no
activity against chymotrypsin and pancreatic elastase (84). In comparison, bovine Intera-Trypsin Inhibitor (BITI)’s C-terminal domain is similar in sequence and activity to
HITI; however, its N-terminal Pi leucine functions as a strong inhibitor of PMN
granulocyte elastase, pancreatic elastase and chymotrypsin (85). The N-terminal domain
of HITI and BITI exemplify how differences in the reactive site amino acid affect the
specificity of individual protease inhibitors.
Other studies demonstrate that substitutions or mutations of the P| amino acid
residue can alter activity of a homologous protease inhibitor. BPTI derivatives with
methionine and valine replacing the Pi residue lysine are strong inhibitors of
chymotrypsin, and chymotrypsin and elastase, respectively (85/72). Mutation of the P|
lysine in Bovine Trypsin Kallikrein Inhibitor to phenylalanine and tryptophan decreased
activity against trypsin and greatly increased inhibition of chymotrypsin (86).
Mutagenesis of the Pi arginine in Alzheimer’s (I-Amyloid Precursor Protein (APP-KD) to
valine changed a trypsin and chymotrypsin inhibitor to a strong inhibitor of human
neutrophil elastase (87). Notable in this study was that the small hydrophobic valine did
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not confer inhibitory activity against chymotrypsin. Altering the amino acid residue at
the reactive site can therefore significantly influence overall inhibitor specificity.
In general, the Pi residue plays a crucial role in the specificity of cognate enzyme
binding. Although we have not determined the active site of rAceKI-1 experimentally,
by comparing it to BPTI, human TFPI, and other Kunitz inhibitors, we can assign the
methionine as the probable P| residue (see figure 15). As mentioned, methionine is a
large hydrophobic residue that binds well to chymotrypsin and has been shown to fit into
the Si cleft of elastase as well (88). Interestingly, rAceKI-1 is also a weak inhibitor of
trypsin. Based on the tight binding kinetics of rAceKI-l’s protein inhibition, it is
surprising that it would have such broad protease inhibitory capacity. There are reported
serine protease inhibitors that have a similar broad spectrum of activity. Ecotin, a unique
inhibitor of chymotrypsin, elastase, and trypsin from E. coli has a Met as its reactive
residue (78). Ecotin’s unusual primary structure does not demonstrate similarities to those
in common families of protease inhibitors. Human ai-proteinase inhibitor inhibits
elastase and chymotrypsin more potently than trypsin, presumably due to the presence of
a methionine occupying its Pi position (89). Streptomyces Subtilisin Inhibitor, a
homologue of Kazal type inhibitors, has a Pi methionine and potently inhibits
chymotrypsin and trypsin (90). Although such broad activity protease inhibitors exist,
AceKI-1 is the first identified from the Kunitz family.
To account for AceKI-1’s unique inhibitory properties, it is important to closely
compare its amino acid sequence to those of other Kunitz inhibitors (see figure 15).
AceKI-1 ’s six cysteine residues clearly align with those of other Kunitz inhibitors, as
does the predicted P] methionine at position 15. As has been shown above, a methionine
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residue at position 15 is consistent with inhibition of chymotrypsin and elastase, but a
large hydrophobic residue does not generally interact with trypsin, and thus does not
explain the weaker trypsin inhibitory activity.

To explain this broader inhibitory

activity, we look at other areas of interaction. The amino acid residues 6-13 (P10-P3) in
Kunitz inhibitors have been shown to play a major role in chemical recognition and
binding interactions with proteases (70). Substitutions in this region rarely affect the
conformation of the external loop but can change the inhibitor’s specificity; however,
only the side chains of the Pi residue, position 15, strongly contact the binding site of the
serine protease. Compared to other Kunitz protease inhibitors, AceKI-1 does have a
unique sequence in the binding domain of residues 12-15, containing a GPQC instead of
the usual GPC. The addition of glutamine at position 13 might play a role in this
P2P1P1

H-TFPI
Rb-TFPI
Rt-TFPI
Mo-TFPI
rAceKI-1
BPTI
ITI/H
IVBB
LNVChyl

C AFKADDGP
C AMKVDDGP CRAYIKRFFFNILAHQCEEFIYGGCEGNENRFESLEECKEKCAR
C AMKAEDGP
C AMKADDGP
CNAPTHLDGP1
C LEPPYTGP
C QLGYSAGP
c ELIVAAGP
c YLPADPGR

5

14

Residue
AceKI-1

30

38

51

55

P4 P3 P2 Pi Pi'P2'P3'Pf
A F F K
P
Q C M

Figure 1 5 : Alignment of rAceKl-1 amino acid sequence with other Kunitz-type inhibitors.
Human tissue factor pathway inhibitor (TFPI) (66), rabbit TFPI (Rb-TFPI) (66), rat TFPI (RtTFPI) (66), mouse TFPI (Mo-TFPI) (91), bovine pancreatic trypsin inhibitor (BPTI) (82), Human
inter-alpha-trypsin inhibitor - domain 1 (ITI/H) (84), venom basic protease inhibitor - eastern
green mamba (IVBB) (70), and Long-nosed viper chymotrypsin inhibitor - Viper ammodytes
(LNVChyl) (82). The method for residue localization is demonstrated with rAceKI-1 showing
P4-P4’. The P| residues at position 15, the reactive site, are bold faced. The six cysteine residues
at positions 5, 14, 30, 38, 51, and 55, predicted to be involved in disulfide bridges, are shaded in
light gray. The underlined amino acid residues 6-13 (Pio-P3) in Kunitz inhibitors have been shown
to play a major role in chemical recognition and binding interactions with proteases. On the edge
of this binding region the conserved GPC is shadowed, and the additional glutamine residue at
position P3 and asparagine residue at position P12 are shaded in dark gray.
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inhibitor’s more unique chemical recognition and target enzyme specificity.
We have therefore postulated our Pi reactive site as a methionine and have
discovered a unique additional glutamine residue in a generally conserved binding region.
We hope to perform site directed mutagenesis at the position 15 methionine measure its
inhibitory activity. It will be interesting to determine if, after changing the reactive site
from methionine to lysine or arginine, chymotrypsin and elastase activity will be lost and
the trypsin activity amplified. We also plan to structurally model this novel protease
inhibitor to see if its additional glutamine residue might increase the area of interface in
the inhibitor:protease complex providing increased stability and therefore broader
activity.
Serine proteases are ubiquitous in nature. As novel inhibitors are identified and
their molecular structures and functions are characterized, it is possible to hypothesize as
to their presumed role in vivo. In studying parasite derived protease inhibitors, similarly,
many investigators have questioned what biologic role these proteins play in parasite
survival.

E. coli produce Ecotin, a periplasmic protein that inhibits chymotrypsin,

elastase, and trypsin. These pancreatic proteases are all present in high concentrations in
the natural environment of the organism leading to the hypothesis that Ecotin is required
for E. coli to survive in the intestine (92). Similarly, the trypsin inhibitor from Fasciola
hepatica is presumed to be involved in parasite survival (82). A pancreatic and

neutrophil elastase inhibitor from the blood fluke Schistosoma mansoni has been
suggested to protect the parasite from neutrophil mediated immune attack (93). We can
likewise postulate that rAceKI-1 is required for protecting hookworm against host
responses, especially in its natural intestinal environment. Interestingly,
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immunohistochemistry performed on the intestinal nematode Ascaris suum, using
antibodies to chymotrypsin and the Ascaris chymotrypsin inhibitor, demonstrated host
chymotrypsin enzyme and Ascaris inhibitor complexes in sections of wonn muscle, eggs,
sperm, and intestines (94). From these results one could argue either that Ascaris are
removing host proteases from their environment for neutralization, or that these are
endogenous proteases that play no role in parasite survival. We have identified AceKI-1
in both adult hookworm extracts and ES products, implying its role is not simply
endogenous to the wonn, but it is secreted or excreted into the parasite’s surrounding
environment. AceKI’s inhibition of trypsin and chymotrypsin may therefore enable the
parasite to survive the hydrolytic environment of the intestine, and its inhibition of
neutrophil elastase might hinder the natural host immune response. By developing a
rabbit antibody to rAceKI-1 and using immunohistochemistry to localize its site of
production and storage in A ceylanicum, we hope to gain a better understanding of
AceKI-l’s biologic role.
While characterizing the role of secreted molecules in hookworm survival,
scientists have questioned the importance of life cycle or stage specificity. The third
stage (L3) infective larvae of Ancylostoma, for example, complete their developmental
molts while in the host. It is hypothesized that Ancylostoma ES products contain
molecules required for completion of these molts, as well as tissue invasion and evasion
of the host immune response (95). These activities of tissue invasion and molting are
stage specific and the translation of genes encoding such proteins may be up regulated
only when developmentally required. We have shown that soluble protein extracts from
adult A. ceylanicum inhibit chymotrypsin, trypsin, pancreatic elastase, and human
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neutrophil elastase. Extracts from infective L3 A. ceylanicum only demonstrate inhibitory
activity against human neutrophil elastase. This evidence suggests that AceKI-1 is a
stage specific inhibitor expressed in adult A. ceylanicum and not the infective L3 stage.
The conserved inhibition of human neutrophil elastase implies the possibility of a second
protease inhibitor. In postulating the in vivo function of AceKI-1, we would expect an
inhibitor of trypsin, chymotrypsin, and pancreatic elastase to be more useful in the adult
stage parasite living in the hydrolytic environment of the intestine.

We therefore more

confidently predict that AceKI-1 has a biologic role in hookworm survival and that such a
virulence factor may serve as a target for chemotherapeutic or vaccine development.
As discussed earlier, no human vaccine exists for hookworm. Current hookworm
control relies on anthelminthic therapy. With growing concern of drug resistance and
prolonged exposure to these potentially toxic chemicals, the search for an alternative
therapy, such as a vaccine, continues. Parasites have unique strategies that make vaccine
development difficult. Hookworms are able to undergo antigenic changes during
development, shed antibody bound surface coats to prevent host recognition, and secrete
immunosuppressive molecules (96). These factors may explain why, although
hookworms induce a host immune response, this response does not appear to protect
against subsequent exposures and development of infection and disease (97). In
identifying a vaccine target, it is important to remember the relationship between
hookworm infection and hookworm disease. Unlike bacteria and viruses, where
eradicating the organism is required for preventing disease, the goal for hookworm
vaccine development may be different.

Eliminating hookworms may not be necessary to

alleviate hookworm anemia; interfering with the parasite’s virulence factors and
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hindering blood loss might be sufficient (98). We must therefore identify what makes a
virulence factor a suitable vaccine target.
Many studies have used natural hookworm antigens in an attempt to induce
immunity to hookworms. For example, by administering infective A. caninum larvae in
numerous small doses, laboratory dogs were protected from challenge with large numbers
of larvae (99).

Regardless of their potentially protective benefit, however, it is not

practical to immunize humans with living hookworm larvae, and additionally, human
exposed to repeated hookworm infections have not developed sterile immunity. Many
hookworm antigens, however, might serve as targets for inducing protective immunity
including somatic antigens and excretory and secretory proteins. Early immunization
trials with hookworm extracts were not successful, possibly due to the low concentration
of potentially protective antigens and the presence of immunosuppressants in the extracts
(96). Another study showed that immunization with either excretory and secretory (ES)
product antigens or somatic antigens from A. ceylanicum yielded high antibody titers, but
ES products provided greater protection (100). Most recently, work in a mouse model
has shown that vaccination with recombinant ASP-1, the most abundantly secreted
protein following activation of A. caninum L3, can reduce lung migration in mice
challenged with infective hookworm larvae (101,102) and pooled antibody from
immunized mice can protect naive mice against hookworm challenge (103). Based on
observations that protective immunity can be generated from hookworm secreted
antigens (104), we hope to create a genetically engineered vaccine for A. ceylanicum
from a secreted antigen such as AceKI-1.
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We have identified AceKI-1 activity in adult hookworm ES products, but there
does not appear to be a natural host immunologic recognition of rAceKI-1. Using our
laboratory hamster model, following forty days of infection with A. ceylanicum, hamster
sera does not recognize recombinant AceKI-1. Hidden antigens are concealed from the
immune system and therefore do not induce a normal immune response, and we
conclude, therefore, that AceKI-1 is a hidden antigen (105,106). Although natural and
overt antigens are more commonly used in vaccine development, hidden antigens can
also be utilized to induce protection. The host inherently recognizes natural antigens as
foreign and generates a humoral antibody response against them.

Since humans for

unknown reasons are unable to induce a protective response to natural hookworm
antigens, a hidden antigen would be an alternative target. In hookworm, for example, if
an antibody is engineered to target a hidden antigen in the parasites intestine, then that
antibody will encounter its target during blood feeding.

Binding the targeted hidden

antigen may interfere with its role in parasite survival as has been demonstrated in
Haemonchus contortus (105).

We believe that AceKI-1 is a virulence factor that aids hookworm survival within
its mammalian host. We have identified a similar inhibitory activity in soluble protein
extracts from other species of adult hookworms, including A. caninum, and Necator
americanus. Such a broadly conserved inhibitory activity further suggests that AceKI-1

may be an evolutionary requirement for hookworm survival. By isolating a new serine
protease inhibitor from hookworm, we hope to better understand how this specific
parasite virulence factor is involved in the pathogenesis of hookworm associated
gastrointestinal blood loss. Because the clinically relevant sequelae of hookworm
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infection depend upon parasite survival in the host environment, interfering with these
protein virulence factors using chemotherapeutics or immunotherapy may represent a
novel strategy to ameliorating hookworm disease.
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